

REMARKS

Informalities


Claims 1-38 are objected to because of certain informalities. Specifically, they should be amended to make it clear that the non-aqueous liquid composition contacts the aqueous dissolution medium. Claims 21 and 22 should be clarified so that it is clear that the pH is optimal for the transfer of the analyte. In response to these objections, Claims 1, 21, and 22 have been amended. Reconsideration of and withdrawal of these objections in view of the amendments is respectfully solicited.

Non-Statutory Obviousness-Type Double Patenting

Claims 1-3, 5-25, 27 and 32-35 have been provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over copending Application No. 10/658,164. Applicants are filing herewith a terminal disclaimer for the term beyond that of copending Application No. 10/658,164. Reconsideration and withdrawal of this provisional rejection in view of the terminal disclaimer is respectfully solicited.

Prompt and favorable consideration of this application is respectfully requested. If the Examiner believes that personal communications will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,



John H. Engelmann, Attorney
Registration No. 28,075

Date: NOVEMBER 13, 2007

Pfizer Inc.
Patent Department
7000 Portage Road
Kalamazoo, Michigan 49001
Telephone No. (269) 833-2532 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316